US2021077610A1PendingUtilityA1

A vaccine to protect a pig against actinobacillus pleuropneumoniae

54
Assignee: INTERVET INCPriority: Dec 20, 2017Filed: Dec 19, 2018Published: Mar 18, 2021
Est. expiryDec 20, 2037(~11.4 yrs left)· nominal 20-yr term from priority
Inventors:Maarten Hendrik WitvlietJohanna Jacoba Elisabeth Bijlsma
A61K 39/102A61P 31/04A61K 2039/54A61K 2039/552A61K 2039/55544C12N 15/866C07K 14/285
54
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention pertains to a vaccine to protect a pig against an infection with Actinobacillus pleuropneumoniae, the vaccine comprising an RTX toxin of Actinobacillus pleuropneumoniae recombinantly expressed by a baculovirus, and a pharmaceutically acceptable carrier.

Claims

exact text as granted — not AI-modified
1 . A vaccine to protect a pig against an infection with  Actinobacillus pleuropneumoniae , the vaccine comprising an RTX toxin of  Actinobacillus pleuropneumoniae  recombinantly expressed by a baculovirus, and a pharmaceutically acceptable carrier. 
     
     
         2 . The vaccine of  claim 1 , wherein the RTX toxin is ApxI. 
     
     
         3 - 6 . (canceled) 
     
     
         7 . A method of protecting a pig against an infection with  Actinobacillus pleuropneumoniae , by administering a vaccine comprising an RTX toxin of  Actinobacillus pleuropneumoniae  recombinantly expressed by a baculovirus and a pharmaceutically acceptable carrier, to the pig. 
     
     
         8 . The method of  claim 7 , wherein the RTX toxin is ApxI. 
     
     
         9 . The method of  claim 8 , wherein the vaccine is administered systemically. 
     
     
         10 . The method of  claim 8 , wherein the vaccine is administered intramuscularly 
     
     
         11 . The method of  claim 8 , wherein the vaccine is administered intradermally. 
     
     
         12 . The method of  claim 7 , wherein the vaccine is administered systemically. 
     
     
         13 . The method of  claim 7 , wherein the vaccine is administered intramuscularly 
     
     
         14 . The method of  claim 7 , wherein the vaccine is administered intradermally.

Join the waitlist — get patent alerts

Track US2021077610A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.